Exploration of molecular signatures associated with different clinical features of Takayasu arteritis based on a prospective cohort study.

ABSTRACT

Takayasu arteritis (TAK) is complicated disorder without reliable biomarkers. Here, we aimed to explore TAK-associated factor panels and their changes after biologic treatment. Five factor panels were identified 1. systemic inflammation C3, ESR, CRP, PLT, IL-6, C4, and IgG; 2. vascular inflammation YKL40, IL-16, PTX3, and CCL2; 3. immune regulation panel IL-10, IFN-γ, CCL5, and MMP1; 4. angiogenesis and fibrosis FGF, PDGFAB, and VEGF; and 5. vascular remodeling CD19+ B cell ratio, MMP3, and leptin. Panel 1 parameters were closely related to disease activity, while Panel 5 parameters, particularly CD19+ B cell ratio and leptin, were significantly higher in ischemic patients. After treatment, tocilizumab had a stronger inhibitory effect on Panel 1 parameters, PTX3, and YKL-40, while adalimumab led to an increase in IL-16, CCL2, and leptin levels. Altogether, these data expanded our knowledge regarding molecular background in TAK development and shed light on precise treatment in future studies.